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Abstract
Background: Population antimicrobial use may influence resistance emergence. Resistance is an ecological
phenomenon due to potential transmissibility. We investigated spatial and temporal patterns of ciprofloxacin (CIP)
population consumption related to E. coli resistance emergence and dissemination in a major Brazilian city. A total
of 4,372 urinary tract infection E. coli cases, with 723 CIP resistant, were identified in 2002 from two outpatient
centres. Cases were address geocoded in a digital map. Raw CIP consumption data was transformed into usage
density in DDDs by CIP selling points influence zones determination. A stochastic model coupled with a
Geographical Information System was applied for relating resistance and usage density and for detecting city areas
of high/low resistance risk.
Results: E. coli CIP resistant cluster emergence was detected and significantly related to usage density at a level of
5 to 9 CIP DDDs. There were clustered hot-spots and a significant global spatial variation in the residual resistance
risk after allowing for usage density.
Conclusions: There were clustered hot-spots and a significant global spatial variation in the residual resistance risk
after allowing for usage density. The usage density of 5-9 CIP DDDs per 1,000 inhabitants within the same
influence zone was the resistance triggering level. This level led to E. coli resistance clustering, proving that
individual resistance emergence and dissemination was affected by antimicrobial population consumption.
Background
Mortality due to infections represents approximately 85%
of all deaths worldwide [1], and community acquired
ones are highly prevalent [1,2]. Furthermore, most of the
community infections present a risk of resistance acquisi-
tion to a first line antimicrobial drug [1]. The increasing
burden of antimicrobial resistance associated to the rela-
tive drought on the antimicrobial developmental pipeline
has urged for strategies to reduce antibiotic consumption
and to maximize treatment approaches [3,4]. These stra-
tegies, as stated by Lipsitch and Samore [3], “rest on the
well-supported idea that the use of antimicrobial agents
is a powerful selective force that promotes the emergence
of resistant strains”. Although infections are ecological
phenomena [3,5-7] and require a new analytical para-
digm, researches have generally taken a case-by-case
approach to understanding the emergence of new infec-
tions or of its consequences [6]. Nevertheless, for any
infectious disease, the infection or colonization status of
a subject affects the acquisition risk of this very same
condition by others and this is due to the transmissibility
risk [3], or the so-called ecological phenomenon. Based
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on this, antibiotic usage as a driver of resistance shall be
equally affected. Should a person or a population be sub-
mitted to an antibiotic usage, other people around who
have not received antibiotics may have increased coloni-
zation or infection risk of acquiring a resistant organism
[3]. Thus, it is reasonable to assume that population anti-
microbial usage may be a major driver in determining
the emergence of resistance in community. However, a
potential population pressure affecting antimicrobial
resistance emergence has not been quantitatively demon-
strated so far.
The EUREQA Project (Epidemiologia do Uso e da
Resistência de Antibióticos e Quimioterápicos na popula-
ção) [8] is a multi-phase spatial and temporal project
aimed at correlating population risk factors, mainly anti-
microbial usage density, with community bacterial resis-
tance. The present study aimed at establishing
quantitative spatial correlations among antimicrobial
usage mean density as measured for the entire popula-
tion and resistance to ciprofloxacin in community urin-
ary tract infections (UTI) caused by E. coli isolated from
adult women in a major urban environment, São Paulo
city, which occupies an area of only 0.02% of the Brazi-
lian Territory with a population of approximately 10.5
million inhabitants.
Methods
The present study has been submitted and approved by
the Ethics Committee of the Federal University of Sao
Paulo (UNIFESP, process CEP 0123/05) and it was
based on data observation without patient identification.
Data
The EUREQA database stores two essential informa-
tions: i) UTI E. coli events by individual address; ii)
antimicrobial selling points. E. coli events had the fol-
lowing case definition: routine urine culture results
positive for E. coli (single isolate per culture, with ≥
100.000 UFC/ml), collected on two large healthcare
outpatient facilities, covering a public and a private
sector unit. Since E. coli occurs most commonly in
female patients, age and sex-specific restrictions were
adopted and only data from female patients with age
higher than 16 years-old were included in this first
analysis. In order to detect resistance clusters, cases
were categorized in susceptible (antibiogram = sensi-
tive) or resistant (antibiogram = resistant or intermedi-
ate) to ciprofloxacin. Ciprofloxacin was the
antimicrobial chosen based on its rapid resistance
development by E. coli and other Gram-negative bac-
teria [9-12]. The antimicrobials selling points were
obtained from a pharmaceutical market auditing com-
pany, IMS Health Brazil, covering 98% of the studied
area. They were categorized as drugstore, delivery
pharmacy, pharmacy chain, hospital, or major distribu-
tor. Those categorized as hospitals and major distribu-
tors were excluded from the final database, which
focused on the community market exclusively. Each
selling point contained monthly Defined Daily Doses
(DDD) information of the all antimicrobials included
in the EUREQA Project (all with ATC code [13]). The
DDD by WHO definition [13] was the basic unit cho-
sen for building a population antimicrobial consump-
tion measurement. For the present study, DDDs for
ciprofloxacin and other quinolones (nalidixic acid, nor-
floxacin, levolfoxacin, gatifloxacin, moxifloxacin) were
kept in the database. For each selling point, a mean
cumulative DDD of a selected antimicrobial (i.e. cipro-
floxacin) for the previous three months (DDDA) was
calculated. Exceptions included the months of the Jan-
uary and February, which used replicated values,
according to the following: January, DDDAJan = 3*
(DDDJan)/3, and February, DDDAFev=(1.5*(DDDJan)
+1.5*(DDDFev)/3. The selection of three months win-
dow accumulated data was based on time-series studies
in hospitals where resistance associated to increased
antimicrobial consumption emerged usually no later
than this timeframe in gram-negatives [10].
Address geocoding
The address geocoding is a procedure to establish the
geographical coordinates of the investigated data based
on street map storage in the database. Then, E. coli
events were address geocoded in a digital map (Figure 1)
by TerraView [14] software. Similarly, each selling point
including ciprofloxacin and other quinolones were
address geocoded. The result is similar to that shown in
Figure 1. At this point we have mapped the distribution
of the E. coli events and antimicrobials selling points
over the city.
Selling points influence zone determination
An influence zone was established for each geocoded
selling point applying Voronoi Diagrams [15-17].
The result is a polygon map covering the study area
(Figure 2), where each polygon represents an influence
zone of the respective selling point. Then, all monthly
DDDA values associated with a particular selling point
was extended to its respective influence zone by Terra-
View [14] software.
Influence zones were used as the best explanation for
consumption pattern, since pharmacy consumption,
either by direct buy or delivery, originates from a zone
closer to the subject`s residence. This way, a DDDA
value initially belonging to a point, was distributed over
an area, basically considering that all individuals over
that area were submitted to that consumption influence.
This procedure was irrespective of individuals actually
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using or not the antimicrobials measured. It only con-
sidered that individuals were under the same consump-
tion influence and, thus, under the same risk for
resistance acquisition due to transmissibility or indirect
effect [3].
Antimicrobial consumption density determination
In order to define a population antimicrobial consump-
tion density the antimicrobial usage mean density
(D_DDDA) was calculated for each influence zone.
Comparison unit was defined as:
D DDDA
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where DDDAk,t is the average of the DDD cumulative
for three months for k-th influence zone and for t-th
month (t = 1,2,..., 12), Popk /1,000 is the estimated
population by a thousand inhabitants restricted to k-th
influence zone and 30 is the number of days in the
month.
The population information is in the census tract
database. To calculate the D_DDDAk,t it is necessary to
estimate Popk the population to each influence zone. It
is done in TerraView [14] through an intersection
operation between the two maps, influence zone and
census tract maps. Then, the population for the k-th
influence zone was estimated as follows:
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where n is the number of the intersections areas that
occurs between the k-th influence zone and the census
tract map, i is the i-th census tract, CTPopi is a popula-
tion of the i-th census tract, CTAreai is the area of the
i-th census tract and INT_Areak,i is the intersection area
between of the k-th influence zone and the i-th census
tract.
Figure 1 Address geocoding of the E. coli cases (resistant and susceptible) in São Paulo city, 2002.
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To illustrate this operation consider the example of
the Figure 3, where the polygons with solid lines repre-
sent the census tract (A, B, C, D, E and F) and the poly-
gon with dashed line represents the k-th influence zone.
The population in the k-th influence zone is equiva-
lent to the weighted sum of the census tract populations
A, B, C, D, E and F. The weight is given by the ratio
between the intersection area (of the k-th influence zone
Figure 2 Selling points influence zones to ciprofloxacin in São Paulo city, 2002.
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with the i-th census tract) and the census tract area.
Thus,
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Finally, each resistant or susceptible case contained
within an influence zone of the respective usage density,
received a value of the respective D_DDDAk,t according
to date of occurrence (closest possible data of the
D_DDDAk,t measurement).
Generalized additive model: a semi-parametric binary
regression approach
To detect resistance clusters in the study area, a spatial
Generalized Additive Model (GAM) [18,19] was
adopted relating E. coli resistance and relevant covari-
ates, spatial and temporal effects. Both the global test
for the spatial variation of resistance risk and the iden-
tification of areas of high/low risk were performed
using the Monte Carlo simulation method proposed by
Kelsall and Diggle [20].
Risk measure
The modeling structure used is based upon a spatial
point process [21] under which a risk measure can be
defined and estimated continuously over the study
region. This procedure firstly defines a risk measure to
detect ciprofloxacin resistant clusters in the study area
A [20]. For this, the susceptible cases are treated as a
sample of the population at risk: the ciprofloxacin non
resistant (susceptible) residents of São Paulo city.
Consider ( )s , s , , sn1 2 1
 the locations of the n1 resis-
tant cases and ( )s , s , , sn n n1 1 1 2+ +
 the locations of the (n
- n1)susceptible cases in the study region A as observa-
tions of two Poisson processes I and II, with intensities
l1 (s) and l2 (s), respectively. A log risk measure at loca-
tion s can be defined as r (s) = log(l1 (s)/l2 (s)) and the
aim is to investigate the spatial variation of r(s) on A.
Risk estimation
A semi-parametric approach to estimating r(s) is used,
called the Generalized Additive Model (GAM) [20].
The GAM method allows estimating the spatial risk
whilst controlling for potential individual or local
environmental factors (such as exposure to D_DDDA,
for instance).
Let yi be an indicator associated to location si , such
that yi = 1 if subject i is a resistant case or 0 otherwise.
Assume that yi(i=1,...,n) are realizations of independent
Bernoulli random variables Yi ~ Bernoulli(p (s)), where
p s
q s
q s q s
,( ) = ( )( ) + ( )
1 1
1 1 2 2
λ
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and q1 and q2 are the sampling proportion of resistant
and susceptible cases in relation to the existing total in
the population. This allows for the possibility of under-
registration under the assumption of missing at random
in space. Under this assumption, it follows that
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Where c = log(q1/q2), so c is simply an additive con-
stant, therefore it does not modify the overall character-
istics of the spatial distribution of the risk over the
region. Hence, one can obtain estimates of r(s), apart
from an additive constant, with a model fitted to a bin-
ary outcome. For easy of interpretation the logarithmic
scale is used with a base 2, as in this scale a unit
increase in the log-risk surface from one location to
another implies the doubling of risk.
Now, for the inclusion of prognostic factor effects, a
logit function can be used to link factor effects and an
additive spatial effect to the probability of resistance p(s),
log
p s x
p s x
x g s ,
( , )
( , )
( )
1 −
⎧⎨⎩
⎫⎬⎭
= + (1)
where x is the vector of individual/local prognostic
factors, b are the effects and g(s) is a smooth (unknown)
function of s.
Figure 3 An example of the population estimation in the k-th
influence zone.
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If the risk is constant then g(s) = 0 and model (Equa-
tion I) becomes the usual logistic regression model [22].
Hence, model (Equation I) is the usual logistic regres-
sion model extended by an additive component g(s), so
the interpretation of factor effects and the spatial effect
are made accordingly.
Then, our model is as follows:
log
p s x
p s x
g s
( , )
( , )
( )
1
D_DDDA I I1 2
−
⎧⎨⎩
⎫⎬⎭
= + + + +   0 1 2 3
where b0: regression model intercept; b1, b2, and b3:
covariates effects; D_DDDA: antimicrobial usage mean
density; I1 = 1 if T1< D_DDDA <T2 and I1 = 0 otherwise;
I2 = 1 if D_DDDA > T2; and I2 = 0 otherwise. E. coli resis-
tance change points (T1 and T2)_were identified after per-
forming an initial analysis on the data by fitting an
ordinary logistic regression model without the spatial term
but allowing for an additive (smooth) effect of D_DDDA
upon the risk of E. coli ciprofloxacin resistance.
Results
The model has shown two major results: i) the probabil-
ity of ciprofloxacin resistance in community UTI E. coli
isolates was associated to population consumption level
between 5 and 9 DDDs/1,000 inhabitants-day (T1 = 5
and T2 = 9), as an accumulated mean for the previous
three months of the occurrence (D_DDDA) (Figure 4);
ii) there was a significant global spatial variation in the
residual risk of resistance (p-value = 0.002) after allow-
ing for D_DDDA with hot-spots clustered in the city
(Figure 5). These areas are delimited by 2.5% and 97.5%
contours resulting approximate 95% tolerance contours
identifying areas of even lower and higher risks, respec-
tively, of E. coli ciprofloxacin resistance than those
expected from the fitted model shown in Figure 4.
Thus, the CIP consumption mean for the entire study
area in year 2002 was 0.6 DDD/1,000 inhabitants-day
and the level of D_DDDA which triggered the occur-
rence of resistance in this study was established between
5 and 9 DDDs of ciprofloxacin/1,000 inhabitants-day.
Additionally, ciprofloxacin D_DDDA was found to be
related to the clusters (Figure 5). However, these ele-
vated risk areas of clustered ciprofloxacin E. coli resis-
tance could have an enhanced risk of presenting other
population covariates associated to its formations.
Additionally a sensitivity analysis was performed and
although correlation between spatial effects and regres-
sion coefficients for spatially varying covariates may be a
general concern, it did not prove relevant for the pre-
sent data analysis. A generalized additive model allowing
for a smooth function of D_DDDA in the linear predic-
tor replacing the change point model together with a
smooth spatial effect was also applied (solid line shown
in Figure 4) and results maintained their significance at
5% level. Furthermore, the presented model has a com-
parable goodness of fit with the GAM model, thus being
chosen for the present study due to its clearer
interpretation.
Discussion and Conclusions
Different epidemiological determinants may favor the
emergence or establishment of specific resistances in
given environments [5,23-25], in particular after shown
that resistance lies within the human commensal bacter-
ial species, which were once considered relatively harm-
less residents of the human microbiome [26]. It also
seems reasonable to speculate that a human-driven
increase in antibiotic concentrations of a given ecosys-
tems, such as a city, may influence both antibiotic resis-
tance and the microbial population dynamics [27]. As
previously noted [3], a population could experience
indirect effects of antimicrobial use, such as an
enhanced risk for resistance acquisition, because of anti-
microbial usage by others in the population. Neverthe-
less, it is still unknown how these different
environmental and individual determinants are distribu-
ted over space and time and their possible influences on
a resistance emergence or clonal spread. It has been
shown by time-series analysis that antimicrobial usage
in a restricted and contained environment, such as a
hospital, is temporally linked to the emergence of bac-
terial resistance [9,10]. However, no correlation of anti-
microbial population usage and bacterial resistance in
the community had been established before the present
study.
The present model used selling points as the basis for
influence zone determination and this concept was sup-
ported by the premise that pharmacy consumption pat-
terns, either by direct buy or delivery, originates from a
zone closer to the subject`s residence. Nevertheless,
authors do acknowledge that potential biases may exist
in this concept, since consumption patterns may also be
related to a subject`s habit of using pharmacies else-
where in the city and that an overestimation of CIP
usage may occur in commercial areas of a city. How-
ever, based on this model, it was found that the level of
D_DDDA which triggered the occurrence of resistance
in this study was established between 5 and 9 DDDs of
CIP/1,000 inhabitants-day and that CIP D_DDDA was
found to be related to the clusters. It means that in a
population of 1,000 inhabitants in a given day, if a mean
of 5 to 9 DDDs of ciprofloxacin had been consumed
over the past three months, E. coli resistance would
occur in subjects of the same geographical area (not
necessarily the same individuals taking the medication).
However, the model could not rule out other population
covariates which might be associated to the elevated risk
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areas of clustered E. coli CIP resistance. Nevertheless,
the model allows for the inclusion of many different
covariates, or risk factors, to be investigated, as long as
they can be geo-referenced, once other population cov-
ariates could be associated to the CIP resistant E. coli
clusters.
We do envisage a combined approach to explore asso-
ciated risk factors, since molecular epidemiology
approaches have given insights into the area. Recently, the
occurrence of an ecological phenomenon has been
demonstrated [24] by a single clonal group accounting for
nearly half of community-acquired urinary tract infections
in women caused by E. coli with resistance to trimetho-
prim-sulfamethoxazole in three geographically diverse
communities. In a different study, a geographical
information system and a Bernoulli regression model were
applied to detect clusters of higher risk of acquisition of S.
aureus soft tissue abscesses [28]. Also, there have been
strategies used with spatial scan statistics to identifying
clusters of samples and to detecting areas with signifi-
cantly high or low sampling rates of a national antimicro-
bial resistance monitoring program [29]. Jones et al. [7]
applied a spatial analysis methodology and found more
than half of emerging infectious diseases events to be
caused by bacteria or rickettsia, with a large number of
drug-resistance and significant correlation with socio-eco-
nomic, environmental and ecological factors. There have
been other significant efforts to understanding resistance
dynamics and transmission with different approaches. It
should be noticed that at least two other strategies [30,31]
Figure 4 E. coli ciprofloxacin resistance probability VS. ciprofloxacin D_DDDA.
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were based on bacterial surveillance data: McCormick et al
[30] have shown patterns of geographic variation
explained by the differences between the proportions of
resistance in specific S. pneumoniae serotypes. Stelling et
al [31] used an electronic laboratory data system
(WHONET) and a space-time permutation scan statistic
for generating a semi-automated detection of disease out-
break with Shigella spp [31]. Both latter approaches seem
to be complimentary to the present one. Furthermore, all
these approaches, including the present one, adopt a
population-level perspective to elucidate the infection
emergence problem and risk factors associated, in particu-
lar the resistance issue.
On the one hand individual-level studies do not pro-
vide the opportunity to observe the ecological phenom-
ena, or indirect effects of treatment on resistance [3,32].
On the other, although avoiding the statistical non-inde-
pendence issue between samples, population-level stu-
dies have not been able to provide a replicable
framework on which one may test the hypothesis of the
indirect effects of treatment on resistance.
The present model has been applied on a longitudinal
observational study, and as such, conclusions are limited
to the environment used, even considering the elevated
sample size and the goodness of fit of model. As a clus-
ter-randomized study of antimicrobial resistance, we
Figure 5 São Paulo city estimated residual (log) risk map showing hot-spots of ciprofloxacin.
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applied the ratio of resistant to susceptible as an end-
point. The spatial clustering of antimicrobial resistance
in this population points to an ecological effect. Never-
theless, the adopted framework allows for the inclusion
of any number of temporal and spatial variables. In par-
ticular, for the study of resistance emergence, it is possi-
ble to fit in the model virtually any antimicrobial-
microorganism combination, in pairs or in groups, if the
objective is to observe class effects. We anticipate our
spatial-temporal modelling strategy embedded into a
geographic information system [33] analytical framework
to be the start-up point for validating, replicating, and
understanding antimicrobial resistance in community
and for public health interventions.
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